ATE321855T1 - Tumor-nekrose-faktor rezeptor 5 - Google Patents

Tumor-nekrose-faktor rezeptor 5

Info

Publication number
ATE321855T1
ATE321855T1 AT98904528T AT98904528T ATE321855T1 AT E321855 T1 ATE321855 T1 AT E321855T1 AT 98904528 T AT98904528 T AT 98904528T AT 98904528 T AT98904528 T AT 98904528T AT E321855 T1 ATE321855 T1 AT E321855T1
Authority
AT
Austria
Prior art keywords
trail
necrosis factor
tumor necrosis
polypeptide
factor receptor
Prior art date
Application number
AT98904528T
Other languages
English (en)
Inventor
Ying-Fei Wei
Jian Ni
Reinhard Ebner
Guo-Liang Yu
Steven M Ruben
Reiner L Gentz
Ping Feng
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Application granted granted Critical
Publication of ATE321855T1 publication Critical patent/ATE321855T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
AT98904528T 1997-01-14 1998-01-13 Tumor-nekrose-faktor rezeptor 5 ATE321855T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3549697P 1997-01-14 1997-01-14
US5488597P 1997-08-07 1997-08-07

Publications (1)

Publication Number Publication Date
ATE321855T1 true ATE321855T1 (de) 2006-04-15

Family

ID=26712172

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98904528T ATE321855T1 (de) 1997-01-14 1998-01-13 Tumor-nekrose-faktor rezeptor 5

Country Status (7)

Country Link
US (2) US6261801B1 (de)
EP (1) EP0990031B1 (de)
JP (1) JP2001505060A (de)
AT (1) ATE321855T1 (de)
AU (1) AU6238698A (de)
DE (1) DE69834027D1 (de)
WO (1) WO1998030693A2 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US6455040B1 (en) * 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
EP0990031B1 (de) 1997-01-14 2006-03-29 Human Genome Sciences, Inc. Tumor-nekrose-faktor rezeptor 5
ATE362982T1 (de) 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
CA2221687A1 (en) * 1997-02-05 1998-08-05 Smithkline Beecham Corporation Tumor necrosis related receptor, tr5
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
AU740227B2 (en) * 1997-06-18 2001-11-01 Genentech Inc. Apo-2DcR
EP1001990A4 (de) * 1997-06-26 2001-12-19 Immunex Corp Trail bindendes protein
JP2001514888A (ja) * 1997-08-15 2001-09-18 アイドゥン ファーマシューティカルズ， インコーポレイテッド Ｔｒａｉｌレセプター、これをコードする核酸、およびその使用方法
AU9376498A (en) * 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
EP1012179A2 (de) * 1997-09-12 2000-06-28 Apotech R&D S.A. Cystein-reiche rezeptoren: trail
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
EP1191940A4 (de) * 1999-05-20 2003-04-02 Human Genome Sciences Inc Tumornekrosefaktor rezeptor 5
CA2382101A1 (en) * 1999-08-25 2001-03-01 Genome Therapeutics Corporation A transmembrane trap for isolating membrane bound proteins
CA2399391A1 (en) * 2000-02-11 2001-08-16 Genetics Institute, Llc. Trade molecules and uses related thereto
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
EP1294949A4 (de) 2000-06-15 2004-08-25 Human Genome Sciences Inc Menschlicher tumornekrosefaktor delta und epsilon
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
MXPA03010747A (es) 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
EP2272946B9 (de) 2002-02-25 2015-06-24 Vaxiion Therapeutics, LLC Minizell-Zusammensetzungen und Verfahren
EP1376134A1 (de) * 2002-06-28 2004-01-02 Universitätsklinikum Charité Medizinische Fakultät der Humboldt-Universität zu Berlin Verfahren zum Screening vom TRAIL-Inhibitoren
KR20080074120A (ko) 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
US20100129358A1 (en) 2006-12-22 2010-05-27 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
DK2346995T3 (en) 2008-09-26 2019-02-11 Tocagen Inc GENETERIVE VECTORS AND CYTOSINDEAMINASES
US9221895B2 (en) 2009-03-13 2015-12-29 The Trustees Of The University Of Pennsylvania OX40/TRAIL fusion proteins
US9725689B2 (en) 2010-10-08 2017-08-08 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
MX361929B (es) 2010-11-19 2018-12-19 Eisai R&D Man Co Ltd Star Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
PE20141562A1 (es) 2011-10-14 2014-11-12 Genentech Inc Anticuerpos anti-htra1 y metodos de uso
EP2909324B1 (de) 2012-10-25 2020-02-26 Tocagen Inc. Retroviraler vektor mit mini-promoter-kassette
GB201307269D0 (en) * 2013-04-23 2013-05-29 Ph Therapeutics Ltd Combination Therapy
EP3068867B1 (de) 2013-11-16 2018-04-18 Terumo BCT, Inc. Zellenexpansion in einem bioreaktor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
EP3198006B1 (de) 2014-09-26 2021-03-24 Terumo BCT, Inc. Geplante fütterung
EP3250219A4 (de) * 2015-01-28 2018-10-03 DNX Biotech, LLC Zusammensetzungen und verfahren zur verwendung eines löslichen modifizierten tnf-alpha-rezeptors für erhöhte halbwertzeit
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
BR112018007703A2 (pt) 2015-10-30 2018-11-06 Genentech Inc anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo
WO2017151940A2 (en) * 2016-03-03 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN105820250B (zh) * 2016-04-29 2019-04-30 中国人民解放军第四军医大学 一种抗basigin人源化抗体及其应用
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
EP4314244B1 (de) 2021-03-23 2025-07-23 Terumo BCT, Inc. Zellerfassung und -erweiterung
WO2023133398A2 (en) * 2022-01-05 2023-07-13 Providence Health & Servces - Oregon Chimeric cd40 polypeptides and methods of use in immunotherapy
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
WO2025071590A1 (en) * 2023-09-27 2025-04-03 R&D Systems, Inc. Human cd30-specific binding proteins and uses thereof
US12122842B1 (en) 2023-09-27 2024-10-22 R&D Systems, Inc. Human CD30-specific binding proteins and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
EP0464533B1 (de) 1990-06-28 1998-07-29 Hoechst Aktiengesellschaft Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
US5783672A (en) * 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
EP0990031B1 (de) 1997-01-14 2006-03-29 Human Genome Sciences, Inc. Tumor-nekrose-faktor rezeptor 5
ATE362982T1 (de) 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
CA2221687A1 (en) 1997-02-05 1998-08-05 Smithkline Beecham Corporation Tumor necrosis related receptor, tr5
US20020102706A1 (en) 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
AU740227B2 (en) 1997-06-18 2001-11-01 Genentech Inc. Apo-2DcR
EP1001990A4 (de) 1997-06-26 2001-12-19 Immunex Corp Trail bindendes protein
JP2001514888A (ja) 1997-08-15 2001-09-18 アイドゥン ファーマシューティカルズ， インコーポレイテッド Ｔｒａｉｌレセプター、これをコードする核酸、およびその使用方法
JP2002505870A (ja) 1998-03-11 2002-02-26 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白およびそれらをコードするポリヌクレオチド

Also Published As

Publication number Publication date
WO1998030693A3 (en) 1998-08-13
DE69834027D1 (de) 2006-05-18
US6261801B1 (en) 2001-07-17
WO1998030693A2 (en) 1998-07-16
EP0990031A2 (de) 2000-04-05
EP0990031B1 (de) 2006-03-29
US20010021516A1 (en) 2001-09-13
AU6238698A (en) 1998-08-03
US7049402B2 (en) 2006-05-23
WO1998030693A9 (en) 1999-09-02
JP2001505060A (ja) 2001-04-17

Similar Documents

Publication Publication Date Title
DE69834027D1 (de) Tumor-nekrose-faktor rezeptor 5
ATE352618T1 (de) Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
AU6250098A (en) Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
DE69837996D1 (de) Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
DE69841140D1 (de) Interleukin-17 rezeptor-ähnliches protein
WO2001055307A8 (en) Nucleic acids, proteins, and antibodies
WO2001054472A3 (en) Nucleic acids, proteins, and antibodies
WO2001055306A3 (en) Nucleic acids, proteins, and antibodies
WO2000066156A8 (en) Death domain containing receptor 5
WO2000056405A3 (en) Human tumor necrosis factor receptor-like 2
WO2001055326A8 (en) Nucleic acids, proteins, and antibodies
EP1178828A4 (de) "death-domain"enthaltender rezeptor
ATE324377T1 (de) Fc-fusionsproteine des menschlichen tumor-nekrose-faktor-rezeptors tr10
WO2001055167A8 (en) Nucleic acids, proteins, and antibodies
WO2001055162A8 (en) Nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties